Increased Toll-Like Receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects

Diabetes Care

Volumn 33, Issue 4, 2010, Pages 861-868

  Dasu, Mohan R ^a   Devaraj, Sridevi ^a   Park, Samuel ^a   Jialal, Ishwarlal ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ENDOTOXIN; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LIGAND; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; MALE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHAPERONIN 60; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; HMGB1 PROTEIN; HSP72 HEAT-SHOCK PROTEINS; HUMANS; HYALURONIC ACID; IMMUNOPRECIPITATION; INTERFERON REGULATORY FACTOR-3; INTERFERON-GAMMA; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTERLEUKIN-1BETA; MONOCYTES; MYELOID DIFFERENTIATION FACTOR 88; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTOR RELA;

EID: 77953060025     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-1799     Document Type: Article

References (25)

1. Haffner SM, Lehto S, Rönnemaa T, PyöräläK, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234
2. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008;4:285-293
3. Dasu MR, Devaraj S, Zhao L, Hwang DH, Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008;57:3090-3098
4. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-1119
5. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006;116:3015-3025
6. Wong FS, Wen L. Toll-like receptors and diabetes. Ann N Y Acad Sci 2008;1150:123-132
7. Curtiss LK, Tobias PS. Emerging role of Toll-like receptors in atherosclerosis. J Lipid Res 2009;50(Suppl.):S340-S345
8. Bagarolli RA, Saad MJ, Saad ST. Toll-like receptor 4 and inducible nitric oxide synthase gene polymorphisms are associated with type 2 diabetes. J Diabetes Complications 2009 Apr 21 (Epub ahead of print)
9. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-376
10. Hill H, Hogan N, Rallison M, Santos JI, Charette RP, Kitahara M. Functional and metabolic abnormalities of diabetic monocytes. Adv Expt Med Biol 1980;69:621-627
11. Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008;93:578-583
12. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukocyte Biol 2004;76:514-519
13. Drage MG, Pecora ND, Hise AG, Febbraio M, Silverstein RL, Golenbock DT, Boom WH, Harding CV. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol 2009;258:29-37
14. Akashi S, Shimazu R, Ogata H, Nagai Y, Takeda K, Kimoto M, Miyake K. Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritonealmacrophages. J Immunol 2000;164:3471-3475
15. Reyna SM, Ghosh S, Tantiwong P, Meka CS, Eagan P, Jenkinson CP, Cers osimo E, Defronzo RA, Coletta DK, Sriwijitkamol A, Musi N. Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 2008;57:2595-2602
16. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007;292:E740-E747
17. Mohammad MK, Morran M, Slotterbeck B, Leaman DW, Sun Y, Grafenstein H, Hong SC, McInerney MF. Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol 2006;18:1101-1113
18. Kim HS, Han MS, Chung KW, Kim S, Kim E, Kim MJ, Jang E, Lee HA, Youn J, Akira S, Lee MS. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 2007;27:321-333
19. Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 2006;346:739-745
20. Devaraj S, Siegel D, Jialal I. Simvastatin (40 mg/day), adiponectin levels, insulin sensitivity, in subjects with the metabolic syndrome. Am J Cardiol 2007;100:1397-1399
21. Devaraj S, Dasu MR, Park S, Jialal I. Increased levels of ligands of TLR2 and TLR4 in type 1 diabetes. Diabetologia 2009;52:1665-1668
22. Liu X, Ukai T, Yumoto H, Davey M, Goswami S, Gibson FC 3rd, Genco CA. Toll-like receptor 2 plays a critical role in the progression of atherosclerosis that is independent of dietary lipids. Atherosclerosis 2007;196:146-154
23. Shinohara M, Hirata K, Yamashita T, Takaya T, Sasaki N, Shiraki R, Ueyama T, Emoto N, Inoue N, Yokoyama M, Kawashima S. Local overexpression of Toll-like receptors at the vessel wall induces atherosclerotic lesion formation: synergism of TLR2 and TLR4. Arterioscler Thromb Vasc Biol 2007;27:2384-2391
24. Du T, Zhou ZG, You S, Huang G, Lin J, Yang L, Li X, Zhou WD, Chao C. Modulation of monocyte hyperresponsiveness to TLR ligands by 1,25-dihydroxy-vitamin D3 from LADA and T2DM. Diabetes Res Clin Pract 2009;83:208-214
25. Wagner H. Endogenous TLR ligands and autoimmunity. Adv Immunol 2006;91:159-173